aTyr Pharma’s lead drug candidate efzofitimod missed its primary endpoint in a Phase 3 trial for pulmonary sarcoidosis, an inflammatory lung disease. The therapy failed to significantly reduce oral corticosteroid use compared to placebo after 48 weeks, leading to an 80% stock drop. Despite the setback, aTyr plans regulatory discussions to explore next steps. The trial results dampen hopes for efzofitimod, a tRNA synthetase-derived immunomodulatory agent targeting activated myeloid cells. This clinical failure casts doubt over aTyr’s near-term prospects and valuation.